Literature DB >> 15276076

Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines.

Leo Veenman1, Evgeny Levin, Gary Weisinger, Svetlana Leschiner, Ilana Spanier, Solomon H Snyder, Abraham Weizman, Moshe Gavish.   

Abstract

The peripheral-type benzodiazepine receptor is found primarily on the outer mitochondrial membrane and consists of three subunits: the 18kDa isoquinoline binding protein, the 32kDa voltage-dependent anion channel, and the 30kDa adenine nucleotide transporter. The current study evaluates the potential importance of peripheral-type benzodiazepine receptor expression in glioma cell tumorigenicity. While previous studies have suggested that peripheral-type benzodiazepine receptor-binding may be relatively increased in tumor tissue and cells, so far, little is known about the relationships between peripheral-type benzodiazepine receptor density and factors underlying tumorigenicity. In the present study, we found in glioma cell lines (C6, U87MG, and T98G), that peripheral-type benzodiazepine receptor ligand-binding density is relatively high for C6 and low for T98G, while U87MG displays intermediate levels. Cell growth of these cell lines in soft agar indicated that high levels of peripheral-type benzodiazepine receptor-binding were associated with increased colony size, indicative of their ability to establish anchorage independent cell proliferation. Potential causes for differences in tumorigenicity between these cell lines were suggested by various cell death and proliferation assays. Cell death, including apoptosis, appeared to be low in C6, and high in T98G, while U87MG displayed intermediate levels in this respect. Cell proliferation appeared to be high in C6, low in T98G, and intermediate in U87MG. In conclusion, our study suggests that relatively high peripheral-type benzodiazepine receptor-binding density is associated with enhanced tumorigenicity and cell proliferation rate. In particular, apoptosis appears to be an important tumorigenic determinant in these glioma cell lines. Moreover, application of PBR-specific ligands indicated that PBR indeed are functionally involved in apoptosis in glioma cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276076     DOI: 10.1016/j.bcp.2004.05.011

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

1.  4'-Chlorodiazepam Protects Mitochondria in T98G Astrocyte Cell Line from Glucose Deprivation.

Authors:  Eliana Baez; Gina Paola Guio-Vega; Valentina Echeverria; Daniel Andres Sandoval-Rueda; George E Barreto
Journal:  Neurotox Res       Date:  2017-04-13       Impact factor: 3.911

Review 2.  Positron emission tomography imaging of neuroinflammation.

Authors:  Annachiara Cagnin; Michael Kassiou; Steve R Meikle; Richard B Banati
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

Review 3.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

4.  Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival.

Authors:  Eugene Vlodavsky; Jean F Soustiel
Journal:  J Neurooncol       Date:  2006-07-26       Impact factor: 4.130

5.  TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma.

Authors:  Hayet Pigeon; Elodie A Pérès; Charles Truillet; Benoit Jego; Fawzi Boumezbeur; Fabien Caillé; Bastian Zinnhardt; Andreas H Jacobs; Denis Le Bihan; Alexandra Winkeler
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

Review 6.  VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis.

Authors:  Leo Veenman; Yulia Shandalov; Moshe Gavish
Journal:  J Bioenerg Biomembr       Date:  2008-06       Impact factor: 2.945

7.  PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect.

Authors:  Tiziana Musacchio; Valentino Laquintana; Andrea Latrofa; Giuseppe Trapani; Vladimir P Torchilin
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

8.  The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.

Authors:  Maria C Mendonça-Torres; Stephen S Roberts
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

9.  Synthesis, Characterization, and in Vitro Evaluation of a New TSPO-Selective Bifunctional Chelate Ligand.

Authors:  Nunzio Denora; Nicola Margiotta; Valentino Laquintana; Angela Lopedota; Annalisa Cutrignelli; Maurizio Losacco; Massimo Franco; Giovanni Natile
Journal:  ACS Med Chem Lett       Date:  2014-03-30       Impact factor: 4.345

10.  TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma.

Authors:  Bastian Zinnhardt; Michael Müther; Wolfgang Roll; Philipp Backhaus; Astrid Jeibmann; Claudia Foray; Cristina Barca; Christian Döring; Bertrand Tavitian; Frédéric Dollé; Matthias Weckesser; Alexandra Winkeler; Sven Hermann; Stefan Wagner; Heinz Wiendl; Walter Stummer; Andreas H Jacobs; Michael Schäfers; Oliver M Grauer
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.